Divi's Laboratories inks manufacturing and supply agreement with global pharma company
News

Divi's Laboratories inks manufacturing and supply agreement with global pharma company

The company expects meaningful revenue contribution from this long-term agreement

  • By IPP Bureau | May 26, 2025

Divi's Laboratories Limited has signed a long term manufacturing and supply agreement with a global pharma company for advanced intermediates.

Under this agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.

The company expects meaningful revenue contribution from this long-term agreement. In view of the confidentiality agreement signed, we are not permitted to disclose name of customer and any quantitative information pertaining to the agreement.

The cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crores, which will be funded from the capacity reservation advance proposed to be paid by the customer phasewise under this Agreement.

The agreement will benefit the customer of assured supply and the Company to expand its presence in custom synthesis.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International